Nurix Therapeutics annual meeting elects directors, ratifies auditor, passes say-on-pay

Nurix Therapeutics, Inc.

All three Class II director nominees elected: Reinsdorf (43.57M for), Saltzman (50.30M for), Baynes (60.82M for).
Ratification of PricewaterhouseCoopers as independent auditor for FY2025 approved (64,950,599 for, 85,040 against).
Non-binding advisory vote on named executive officer compensation passed (49,788,975 for, 11,341,365 against).
Annual meeting held May 19, 2025; 65,056,197 shares (85.33% of voting power) constituted a quorum.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.